Potential Uncertainty Reduction in Model-Averaged Benchmark Dose Estimates Informed by an Additional Dose Study

Risk Analysis

Volumn 31, Issue 10, 2011, Pages 1561-1575

  Shao, Kan ^a,b   Small, Mitchell J ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Bayesian model averaging (BMA); Benchmark dose (BMD); Dose response modeling; Markov chain Monte Carlo (MCMC); Preposterior analysis; TCDD

Indexed keywords

BAYESIAN MODEL AVERAGING; BENCHMARK DOSE; DOSE-RESPONSE MODELING; MARKOV CHAIN MONTE CARLO; PREPOSTERIOR ANALYSIS; TCDD;

BAYESIAN NETWORKS; BIOASSAY; COMPUTER SIMULATION; ESTIMATION; FORECASTING; HEALTH RISKS; MARKOV PROCESSES; MONTE CARLO METHODS; PARAMETER ESTIMATION;

UNCERTAINTY ANALYSIS;

BAYESIAN ANALYSIS; BENCHMARKING; BIOASSAY; CARCINOGEN; DATA SET; DOSE-RESPONSE RELATIONSHIP; ESTIMATION METHOD; MARKOV CHAIN; MONTE CARLO ANALYSIS; NUMERICAL MODEL; PARAMETERIZATION; PREDICTION; RISK ASSESSMENT; TCDD; TOXICITY TEST; UNCERTAINTY ANALYSIS;

ANIMAL; ARTICLE; BAYES THEOREM; DOSE RESPONSE; HUMAN; MONTE CARLO METHOD; THEORETICAL MODEL; UNCERTAINTY;

ANIMALS; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, THEORETICAL; MONTE CARLO METHOD; UNCERTAINTY;

EID: 80054115780     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2011.01595.x     Document Type: Article

References (33)

1. ICRP (International Commission on Radiological Protection). Report of the Task Group on Reference Man. ICRP Publication 23. Oxford Pergamon Press, 1975.
2. ICRP (International Commission on Radiological Protection). Recommendations of the International Commission on Radiological Protection. ICRP Publication 26. Annals of the ICRP 1(3). Oxford Pergamon Press, 1977.
3. Barnes DG, Dourson M, Preuss P, Bellin J, Derosa C, Erdreich L. et al. Reference dose (RfD): Description and use in health risk assessments. Regulatory Toxicology and Pharmacology, 1988; 8(4):471-486.
4. Crump KS. A new method for determining allowable daily intakes. Fundamental and Applied Toxicology, 1984; 4(5):854-871.
5. Piegorsch WW, West RW. Benchmark analysis: Shopping with proper confidence. Risk Analysis, 2005; 25(4):913-920.
6. Taylor AC, Evans JS, McKone TE. The value of animal test information in environmental control decisions. Risk Analysis, 1993; 13(4):403-412.
7. Yokota F, Thompson KM. Value of information analysis in environmental health risk management decisions: Past, present, and future. Risk Analysis, 2004; 24(3):635-650.
8. Kociba RJ, Keyes DG, Beyer JE, Carreon RM, Wade CE, Dittenber DA. et al. Results of a two-year chronic toxicity and oncogenicity study of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in rats. Toxicology and Applied Pharmacology, 1978; 46(2):279-303.
9. NTP (National Toxicology Program). Carcinogenesis Bioassay of 2, 3, 7, 8-Tetrachlorodibenzo-p-Dioxin (CAS No. 1746-01-6) in Osborne-Mendel Rats and B6C3F1 Mice (Gavage Study). NTP Technical Report No. 209. NTP-80-31. NIH 82-1765. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program, Research Triangle Park, NC, and Bethesda, MD, 1982.
10. Dakins ME, Toll JE, Small MJ, Brand KP. Risk-based environmental remediation: Bayesian Monte Carlo analysis and the expected value of sample information. Risk Analysis, 1996; 16(1):67-79.
11. Müller P. Simulation-based optimal design. Pp. 459-474 in Bernardo JM, Berger JO, Dawld AP, Smith AFM (eds). Bayesian Statistics 6. Oxford, UK Oxford University Press, 1999.
12. Sohn MD, Small MJ, Pantazidou M. Reducing uncertainty in site characterization using Bayes Monte Carlo methods. Journal of Environmental Engineering, 2000; 126(10):893-902.
13. Ades AE, Lu G, Claxton K. Expected value of sample information in medical decision modelling. Medical Decision Making, 2004; 24(2):207-227.
14. Choi T., Schervish MJ, Schmitt KA, Small MJ Bayesian hierarchical analysis for multiple health endpoints in a toxicity study. Journal of Agricultural, Biological, and Environmental Statistics, 2010; 15(3):290-307.
15. Van Miller JP, Lalich JJ, Allen JR. Increased incidence of neoplasms in rats exposed to low levels of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Chemosphere, 1977; 6:537-544.
16. Rao MS, Subbarao V, Prasas JD, Scarpelli DG. Carcinogenicity of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in the Syrian golden hamster. Carcinogenesis, 1988; 9(9):1677-1679.
17. Johnson R, Tietge J, Botts S. Carcinogenicity of 2, 3, 7, 8-TCDD to Medaka. Toxicologist, 1992; 12:476.
18. U.S. EPA (U.S. Environmental Protection Agency). Exposure and Human Health Reassessment of 2, 3, 7, 8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds National Academy Sciences (NAS) Review Draft, 2003; Part II Chapter 6. EPA/600/P-00/001Cb. Available at.
19. Birnbaum LS. The mechanism of dioxin toxicity: Relationship to risk assessment. Environmental Health Perspectives, 1994; 102(9):157-167.
20. NRC (National Research Council). Health risks from dioxin and related compounds: Evaluation of the EPA reassessment. NRC, Board on Environmental Studies and Toxicology (BEST). Washington, DC National Academies Press, 2006.
21. Barnes DG, Daston GP, Evans JS, Jarabek AM, Kavlock RJ, Kimmel CA, Park C and Spitzer HL. Benchmark dose workshop: Criteria for use of a benchmark dose to estimate a reference dose. Regulatory Toxicology and Pharmacology, 1995; 21:296-306.
22. Faustman EM, Bartell SM. Review of noncancer risk assessment: Applications of benchmark dose methods. Human and Ecological Risk Assessment, 1997; 5(3):893-920.
23. Filipsson AF, Sand S, Nilsson J, Victorin K. The benchmark dose method: Review of available models, and recommendations for application in health risk assessment. Critical Reviews in Toxicology, 2003; 33(5):505-542.
24. U.S. EPA (U.S. Environmental Protection Agency). Benchmark Dose Technical Guidance Document. External Review Draft, 2000. EPA/630/R-00/001. Available at.
25. Viallefont V, Raftery AE, Richardson S. Variable selection and Bayesian model averaging epidemiological case-control studies. Statistics in Medicine, 2001; 20(21): 3215-3230.
26. Brown PJ, Vannucci M, Fearn T. Multivariate Bayesian variable selection and prediction. Journal of the Royal Statistical Society (Series B: Statistical Methodology), 1998; 60(3):627-641.
27. Volinsky CT, Madigan D, Raftery AE, Kronmal RA. Bayesian model averaging in proportional hazard models: Predicting the risk of a stroke. Journal of the Royal Statistical Society (Series C: Applied Statistics), 1997; 46(4): 433-448.
28. Raftery AE, Madigan D, Hoeting JA. Bayesian model averaging for linear regression models. Journal of the American Statistical Association, 1997; 92(437):179-191.
29. Wasserman L. Bayesian model selection and model averaging. Journal of Mathematical Psychology, 2000; 44(1):92-107.
30. U.S EPA (Environmental Protection Agency). Benchmark Dose Software (BMDS) Version 2.1.2 (Build 60). (11 June 2010). U.S. EPA National Center for Environmental Assessment, Washington, DC Available at: (last updated on August 13, 2010).
31. U.S EPA (Environmental Protection Agency). Benchmark Dose (BMD) Methodology. U.S. EPA National Center for Environmental Assessment, Washington, DC Available at: (last updated on June 16, 2010).
32. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control, 1974, AC-19:716-723.
33. Burnham KP, Anderson DR. Multimodel inference: Understanding AIC and BIC in model selection. Sociological Methods and Research 2004, 33:261-304.